127 related articles for article (PubMed ID: 18611421)
1. Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process.
Kempe S; Metz H; Mäder K
J Control Release; 2008 Sep; 130(3):220-5. PubMed ID: 18611421
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive in vivo evaluation of in situ forming PLGA implants by benchtop magnetic resonance imaging (BT-MRI) and EPR spectroscopy.
Kempe S; Metz H; Pereira PG; Mäder K
Eur J Pharm Biopharm; 2010 Jan; 74(1):102-8. PubMed ID: 19545625
[TBL] [Abstract][Full Text] [Related]
3. Monitoring release of ketoprofen enantiomers from biodegradable poly(D,L-lactide-co-glycolide) injectable implants.
Wang SH; Liang ZH; Zeng S
Int J Pharm; 2007 Jun; 337(1-2):102-8. PubMed ID: 17296274
[TBL] [Abstract][Full Text] [Related]
4. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.
Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive in vivo characterization of microclimate pH inside in situ forming PLGA implants using multispectral fluorescence imaging.
Schädlich A; Kempe S; Mäder K
J Control Release; 2014 Apr; 179():52-62. PubMed ID: 24503251
[TBL] [Abstract][Full Text] [Related]
6. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles.
Kranz H; Bodmeier R
Eur J Pharm Sci; 2008 Jul; 34(2-3):164-72. PubMed ID: 18501569
[TBL] [Abstract][Full Text] [Related]
7. In-situ forming PLGA implants for intraocular dexamethasone delivery.
Bode C; Kranz H; Siepmann F; Siepmann J
Int J Pharm; 2018 Sep; 548(1):337-348. PubMed ID: 29981408
[TBL] [Abstract][Full Text] [Related]
8. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release.
Parent M; Nouvel C; Koerber M; Sapin A; Maincent P; Boudier A
J Control Release; 2013 Nov; 172(1):292-304. PubMed ID: 24001947
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic analysis of PLGA/HPMC-based in-situ forming implants for periodontitis treatment.
Do MP; Neut C; Metz H; Delcourt E; Siepmann J; Mäder K; Siepmann F
Eur J Pharm Biopharm; 2015 Aug; 94():273-83. PubMed ID: 26047797
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive characterization of in situ forming implants using diagnostic ultrasound.
Solorio L; Babin BM; Patel RB; Mach J; Azar N; Exner AA
J Control Release; 2010 Apr; 143(2):183-90. PubMed ID: 20060859
[TBL] [Abstract][Full Text] [Related]
11. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
Kranz H; Bodmeier R
Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
[TBL] [Abstract][Full Text] [Related]
12. In-situ forming PLGA implants: Towards less toxic solvents.
Ramos F; Willart JF; Neut C; Agossa K; Siepmann J; Siepmann F
Int J Pharm; 2024 May; 657():124121. PubMed ID: 38621617
[TBL] [Abstract][Full Text] [Related]
13. Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability.
Ahmed TA; Ibrahim HM; Samy AM; Kaseem A; Nutan MT; Hussain MD
AAPS PharmSciTech; 2014 Jun; 15(3):772-80. PubMed ID: 24648158
[TBL] [Abstract][Full Text] [Related]
14. Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol.
Ahmed TA; Ibrahim HM; Ibrahim F; Samy AM; Kaseem A; Nutan MT; Hussain MD
J Pharm Sci; 2012 Oct; 101(10):3753-62. PubMed ID: 22753324
[TBL] [Abstract][Full Text] [Related]
15. Injectable in situ forming depot systems: PEG-DAE as novel solvent for improved PLGA storage stability.
Schoenhammer K; Petersen H; Guethlein F; Goepferich A
Int J Pharm; 2009 Apr; 371(1-2):33-9. PubMed ID: 19135512
[TBL] [Abstract][Full Text] [Related]
16. A novel injectable in situ forming poly-DL-lactide and DL-lactide/glycolide implant containing lipospheres for controlled drug delivery.
Yehia SA; Elshafeey AH; Elsayed I
J Liposome Res; 2012 Jun; 22(2):128-38. PubMed ID: 22091557
[TBL] [Abstract][Full Text] [Related]
17. In situ micro-sized gel-forming injectable implant using biodegradable amphiphilic graft copolymer.
Cho KY; Lee S; Park JK
Macromol Biosci; 2007 Jun; 7(6):784-8. PubMed ID: 17541923
[TBL] [Abstract][Full Text] [Related]
18. Effect of injection site on in situ implant formation and drug release in vivo.
Patel RB; Solorio L; Wu H; Krupka T; Exner AA
J Control Release; 2010 Nov; 147(3):350-8. PubMed ID: 20728486
[TBL] [Abstract][Full Text] [Related]
19. Initial Leuprolide Acetate Release from Poly(d,l-lactide-
Li Z; Mu H; Larsen SW; Jensen H; Østergaard J
Mol Pharm; 2020 Dec; 17(12):4522-4532. PubMed ID: 33164519
[TBL] [Abstract][Full Text] [Related]
20. In-situ forming composite implants for periodontitis treatment: How the formulation determines system performance.
Do MP; Neut C; Metz H; Delcourt E; Mäder K; Siepmann J; Siepmann F
Int J Pharm; 2015; 486(1-2):38-51. PubMed ID: 25791762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
